Gene Editing Stocks Drop Following Anthropic's AI Discovery
Stocks in the gene editing sector declined on Wednesday after Anthropic announced that its AI model, Claude, had autonomously discovered a new enzyme system similar to CRISPR. The development raised concerns about potential disruptions or advancements in genetic engineering technologies driven by artificial intelligence. Notable companies affected included Beam Therapeutics and CRISPR Therapeutics, both of which saw their shares fall as investors reacted to the news. While Anthropic did not provide immediate commercial applications for its discovery, market participants interpreted it as a sign that AI could play an increasingly significant role in biotechnology innovation. The broader impact on the sector remains uncertain at this stage, but the announcement has sparked discussions about how traditional gene-editing firms might compete with AI-driven discoveries.
Tickers: $BEAM
Topics: AI discovery biotech stocks CRISPR gene editing